According to new research at Washington University School of Medicine in St. Louis, a substance shown to counteract aspects of aging in healthy mice was proven to increase glucose uptake in humans in a small clinical trial.
Learn more about glucose uptake:
These clinical studies looked into postmenopausal women with prediabetes who were treated with NMN (nicotinamide mononucleotide). The NMN treatment improved the ability of insulin to increase glucose uptake in skeletal muscle that is often impaired in people with obesity, prediabetes or Type 2 diabetes. Findings were reported in the journal Science and was the first to discuss the metabolic effects of NMN administration in humans.
"Although our study shows a beneficial effect of NMN in skeletal muscle, it is premature to make any clinical recommendations based on the results from our study," said senior investigator Samuel Klein, MD, the William H. Danforth Professor of Medicine and Nutritional Science and director of the Center for Human Nutrition. "Normally, when a treatment improves insulin sensitivity in skeletal muscle, as is observed with weight loss or some diabetes medications, there also are related improvements in other markers of metabolic health, which we did not detect in our study participants."
Source: Science Daily
